Epstein Files

EFTA01943189.pdf

dataset_10 PDF 101.9 KB Feb 4, 2026 1 pages
To: Lesley Gro1 From: Jeffrey Epstein Sent Wed 12/4/2013 5:19:06 PM Subject: Re: Joe Thakuria have him send an invoice On Wed, Dec 4, 2013 at 11:16 AM, Lesley Groff wrote: from Joe Thakuria...a follow up to his last email... It's exciting since with the exception of the clinical whole genome (that Illumina has offered for years but at a very low volume due to cost and very limited clinical indication (for now)), the other stuff (including the clinical exomes) hasn't really even been around beyond a year or so. The iPS cell lines would have been something you could only get from a handful of labs worldwide and, even then, the researchers would most likely be prioritizing their own projects - not doing "one-off" individualized cell lines for interested parties. Anyway, I'll make sure he gets access to the latest and greatest and he can choose those things that are of the greatest scientific and personal interest for him from the list. Maybe along the way also help some of these kids with genetic disorders that we haven't been able to molecularly diagnose through conventional Sanger sequencing at MGH. Cheers, Joe The information contained in this communication is confidential, may be attorney-client privileged, may constitute inside information, and is intended only for the use of the addressee. It is the property of Jeffrey Epstein Unauthorized use, disclosure or copying of this communication or any part thereof is strictly prohibited and may be unlawful. If you have received this communication in error, please notify us immediately by return e-mail or by e-mail to jtevacatioila umail.com and destroy this communication and all copies thereof, including all attachments. copyright -all rights reserved EFTA_R1_00403569 EFTA01943189

Entities

0 total entities mentioned

No entities found in this document

Document Metadata

Document ID
66fe5bb2-a90f-446a-b3eb-f70712956b41
Storage Key
dataset_10/faad/EFTA01943189.pdf
Content Hash
faad29fa182eec8a8a38a6cba12acb22
Created
Feb 4, 2026